Recombinant Penicillium marneffei Methylthioribose-1-phosphate isomerase (mri1)

What is the biochemical function of Methylthioribose-1-phosphate isomerase (MRI1) in Penicillium marneffei?

Methylthioribose-1-phosphate isomerase (MRI1) in P. marneffei primarily catalyzes the interconversion of methylthioribose-1-phosphate (MTR-1-P) into methylthioribulose-1-phosphate (MTRu-1-P) . This isomerization represents a critical step in the methionine salvage pathway, which allows the organism to recycle sulfur-containing metabolites. Beyond this catalytic function, MRI1 has been found to promote cell invasion processes in response to constitutive RhoA activation by facilitating FAK tyrosine phosphorylation and stress fiber turnover . This dual functionality makes MRI1 particularly interesting for researchers studying both metabolic pathways and virulence mechanisms in P. marneffei.

For characterization studies, researchers should employ enzyme activity assays that measure the conversion rate between MTR-1-P and MTRu-1-P under varying conditions. Typically, this involves spectrophotometric methods coupled with auxiliary enzymes or HPLC-based detection of substrate depletion and product formation. Experimental controls should include heat-inactivated enzyme preparations and reactions lacking key cofactors.

What role does MRI1 potentially play in the pathogenesis of P. marneffei infections?

P. marneffei is a dimorphic fungus endemic to Southeast Asia that causes potentially fatal penicilliosis, particularly in immunocompromised individuals such as those with HIV . While the direct role of MRI1 in pathogenesis is not explicitly detailed in the available literature, its non-catalytic function in promoting cell invasion suggests potential involvement in virulence mechanisms .

To investigate this question, researchers should:

• Generate MRI1 knockout or knockdown strains using CRISPR-Cas9 or RNAi techniques

• Compare virulence between wild-type and MRI1-deficient strains in appropriate infection models

• Perform transcriptomic analysis of MRI1 expression during different stages of infection

• Investigate MRI1 expression in different morphological forms (yeast vs. mycelial) of P. marneffei

• Examine the interaction between MRI1 and host cell proteins during invasion processes

The research approach should incorporate both in vitro invasion assays using relevant human cell lines and in vivo infection models that replicate key aspects of penicilliosis pathogenesis.

What are the optimal expression systems for producing recombinant P. marneffei MRI1?

When selecting an expression system for recombinant P. marneffei MRI1, researchers should consider several factors including protein solubility, post-translational modifications, and downstream applications. While the literature doesn't specify an optimal system for P. marneffei MRI1 specifically, experiences with other fungal proteins suggest several viable approaches.

For eukaryotic expression, Pichia pastoris has proven effective for expressing other P. marneffei proteins as demonstrated in studies with Mp1p . This system offers advantages for fungal proteins requiring disulfide bonds or glycosylation. Methodologically, researchers should:

• Clone the MRI1 gene with appropriate tags (His, GST, or FLAG) for purification

• Optimize codon usage for the selected expression host

• Test multiple promoter systems (constitutive vs. inducible)

• Evaluate expression at varying temperatures (20-30°C) to enhance solubility

• Compare intracellular expression versus secretion strategies

For prokaryotic expression, E. coli systems (BL21, Rosetta, or Arctic Express strains) provide high yields but may require refolding protocols if inclusion bodies form. Expression should be tested at lower temperatures (16-25°C) with varying IPTG concentrations to maximize soluble protein yields.

What purification strategies yield the highest purity and activity for recombinant P. marneffei MRI1?

A multi-step purification strategy typically yields the best results for recombinant enzymes like MRI1. While specific protocols for P. marneffei MRI1 are not detailed in the search results, the following methodological approach is recommended:

• Initial capture using affinity chromatography:

  • If His-tagged: Immobilized metal affinity chromatography (IMAC) with Ni-NTA or Co-NTA resins

  • If GST-tagged: Glutathione Sepharose

  • If FLAG-tagged: Anti-FLAG antibody resins

• Intermediate purification:

  • Ion exchange chromatography based on the predicted isoelectric point of MRI1

  • Hydrophobic interaction chromatography as an orthogonal technique

• Polishing step:

  • Size exclusion chromatography to remove aggregates and achieve final purity

Throughout purification, researchers should:

• Add protease inhibitors to prevent degradation

• Include reducing agents if MRI1 contains critical cysteine residues

• Test enzyme activity after each purification step to track specific activity

• Optimize buffer conditions (pH, salt concentration, glycerol content) to maintain stability

The final preparation should be assessed using SDS-PAGE, Western blotting, and activity assays to confirm purity and functionality.

How can I troubleshoot expression problems with recombinant P. marneffei MRI1?

When facing challenges with recombinant MRI1 expression, a systematic troubleshooting approach is essential:

• For low expression yields:

  • Verify sequence integrity and codon optimization

  • Test different promoter systems and expression conditions

  • Ensure proper induction timing and concentration

  • Consider co-expression with chaperones for improved folding

• For insoluble protein or inclusion body formation:

  • Reduce expression temperature to 16-20°C

  • Decrease inducer concentration

  • Add solubility enhancers (sorbitol, glycerol, or mild detergents)

  • Test fusion partners known to enhance solubility (SUMO, MBP, or TrxA)

  • Develop refolding protocols from inclusion bodies if necessary

• For protein degradation:

  • Add protease inhibitors during all steps

  • Test expression in protease-deficient strains

  • Optimize lysis and purification buffers

  • Reduce handling time and maintain samples at 4°C

• For inactive protein:

  • Verify proper folding using circular dichroism or limited proteolysis

  • Test different buffer conditions for stabilization

  • Consider co-factors or metals that might be required for activity

  • Evaluate the impact of tags on enzyme function

Each troubleshooting step should be documented with appropriate controls to identify the specific factors affecting expression outcomes.

What enzymatic assays are most effective for measuring P. marneffei MRI1 activity?

To effectively measure the catalytic activity of recombinant P. marneffei MRI1, researchers should consider several complementary approaches:

• Direct spectrophotometric assays:

  • Monitor the absorbance changes associated with the isomerization reaction

  • Develop a coupled enzyme assay where the product (MTRu-1-P) serves as substrate for a subsequent enzyme with easily detectable activity

• Chromatographic methods:

  • HPLC separation and quantification of substrates and products

  • LC-MS/MS for definitive identification and quantification

• Radiometric assays:

  • Use radiolabeled substrates (14C or 3H-labeled) to track conversion rates

  • Separate products by TLC or ion-exchange chromatography

The optimal assay conditions should be determined experimentally by varying:

• pH (typically testing a range of 6.0-8.5)

• Temperature (25-40°C)

• Buffer composition

• Divalent cation requirements (Mg2+, Mn2+)

• Substrate concentration ranges for kinetic analysis

For kinetic characterization, researchers should determine:

• Km and Vmax values through Michaelis-Menten analysis

• Effects of potential inhibitors

• pH and temperature optima

• Substrate specificity by testing related compounds

These assays provide the foundation for understanding the catalytic properties of MRI1 and establishing a baseline for further functional studies.

How can I investigate the non-catalytic functions of P. marneffei MRI1 in cell invasion processes?

The non-catalytic role of MRI1 in promoting cell invasion through FAK tyrosine phosphorylation and stress fiber turnover represents an interesting area for investigation. Researchers should employ the following methodological approaches:

• Site-directed mutagenesis studies:

  • Generate catalytically inactive mutants that maintain structural integrity

  • Create truncation variants to map domains responsible for non-catalytic functions

  • Design mutants specifically targeting potential protein-protein interaction sites

• Protein-protein interaction studies:

  • Perform co-immunoprecipitation with potential binding partners

  • Use yeast two-hybrid or mammalian two-hybrid systems to identify interactors

  • Apply proximity labeling approaches (BioID or APEX) to identify the MRI1 interactome

  • Conduct pull-down assays with recombinant MRI1 and cell lysates

• Cell-based functional assays:

  • Develop invasion assays using relevant human cell lines

  • Quantify FAK phosphorylation levels by Western blotting or ELISA

  • Visualize stress fiber formation using fluorescent phalloidin staining

  • Perform live-cell imaging to track dynamic changes in cytoskeletal organization

• Signaling pathway analysis:

  • Use specific inhibitors of RhoA and downstream effectors

  • Assess the impact of MRI1 on related signaling components

  • Perform phosphoproteomics to identify changes in cellular phosphorylation patterns

Each experiment should include appropriate controls, including wild-type MRI1, catalytically inactive mutants, and vector-only controls to distinguish between catalytic and non-catalytic effects.

What methods are most suitable for studying MRI1's role in the methionine salvage pathway of P. marneffei?

To investigate MRI1's role in the methionine salvage pathway of P. marneffei, researchers should employ a combination of genetic, biochemical, and metabolomic approaches:

• Genetic manipulation:

  • Generate MRI1 knockout strains using CRISPR-Cas9 or homologous recombination

  • Create conditional expression systems to modulate MRI1 levels

  • Complement knockout strains with wild-type or mutant MRI1 variants

• Growth phenotype analysis:

  • Assess growth in media with limited methionine sources

  • Compare growth rates when providing different sulfur-containing metabolites

  • Evaluate stress responses related to sulfur metabolism

• Metabolomic profiling:

  • Quantify intracellular levels of methionine and related metabolites

  • Track metabolic flux using isotope-labeled precursors

  • Measure the accumulation of pathway intermediates in MRI1-deficient strains

• Transcriptomic response:

  • Analyze expression changes in other methionine salvage pathway genes

  • Compare transcriptional profiles under methionine-rich versus limiting conditions

  • Identify potential regulatory connections between MRI1 and other metabolic pathways

• In vitro pathway reconstitution:

  • Express and purify multiple enzymes from the pathway

  • Reconstitute the sequential enzymatic reactions in vitro

  • Assess rate-limiting steps and regulatory points

These approaches collectively provide a comprehensive understanding of how MRI1 contributes to methionine metabolism in P. marneffei and how this pathway might influence pathogenesis.

How can structural biology approaches advance our understanding of P. marneffei MRI1?

Structural biology techniques provide critical insights into enzyme function, regulation, and potential for drug targeting. For P. marneffei MRI1, researchers should consider:

• X-ray crystallography approaches:

  • Optimize protein crystallization conditions (screening hundreds of conditions)

  • Co-crystallize with substrates, products, or inhibitors

  • Solve structures at different pH values or with different bound ligands

  • Compare structures of wild-type and mutant variants

• Cryo-electron microscopy:

  • Particularly valuable if MRI1 forms larger complexes with interaction partners

  • Can reveal conformational dynamics not captured in crystal structures

  • Suitable for proteins resistant to crystallization

• NMR spectroscopy:

  • For studying solution dynamics and conformational changes

  • Identifying binding sites through chemical shift perturbation experiments

  • Characterizing intrinsically disordered regions

• Computational approaches:

  • Molecular dynamics simulations to study protein flexibility

  • Docking studies with potential inhibitors

  • Prediction of allosteric sites

  • Free energy calculations for binding interactions

• Small-angle X-ray scattering (SAXS):

  • For low-resolution envelopes of the protein in solution

  • Studying conformational changes upon ligand binding

  • Complementary to high-resolution techniques

The structural data should be integrated with functional studies to correlate structural features with both catalytic and non-catalytic functions of MRI1, potentially revealing mechanisms that could be targeted for therapeutic intervention in P. marneffei infections.

What are the best approaches for developing inhibitors targeting P. marneffei MRI1?

Developing inhibitors against P. marneffei MRI1 represents a potential strategy for antifungal therapeutics. Researchers should adopt a multi-faceted approach:

• Structure-based design:

  • Utilize crystal structures or homology models to identify active site features

  • Design compounds that mimic transition states or high-energy intermediates

  • Target allosteric sites that may affect both catalytic and non-catalytic functions

  • Apply molecular docking and virtual screening of compound libraries

• High-throughput screening:

  • Develop a robust, plate-based assay suitable for screening thousands of compounds

  • Consider fluorescence-based, colorimetric, or bioluminescent readouts

  • Include counter-screens against human homologs to identify selective inhibitors

• Fragment-based drug discovery:

  • Screen libraries of low-molecular-weight fragments

  • Use NMR, SPR, or X-ray crystallography to detect weak binders

  • Link or grow fragments to develop high-affinity leads

• Rational design based on substrate analogs:

  • Synthesize substrate mimetics with non-hydrolyzable features

  • Develop transition-state analogs based on reaction mechanism

  • Incorporate reactive groups that form covalent bonds with active site residues

• Evaluation pipeline:

  • Biochemical assays for direct inhibition of enzymatic activity

  • Cellular assays measuring impact on P. marneffei growth and invasion

  • Selectivity testing against human homologs

  • ADME and toxicity profiling for promising candidates

The most successful inhibitor development programs typically combine multiple approaches and iterate through design-synthesis-testing cycles to optimize potency, selectivity, and drug-like properties.

How can I design experiments to investigate the role of MRI1 in P. marneffei adaptation to environmental stress?

P. marneffei is a thermally dimorphic fungus that transitions between mycelial (25°C) and yeast (37°C) forms, representing adaptation to environmental versus host conditions . To investigate MRI1's potential role in this adaptation process, researchers should:

• Expression and localization studies:

  • Compare MRI1 expression levels between morphological forms using RT-qPCR and Western blotting

  • Examine subcellular localization using fluorescently tagged MRI1

  • Analyze promoter activity under different stress conditions

• Stress response experiments:

  • Expose wild-type and MRI1-deficient strains to various stressors:

    • Temperature shifts (25°C to 37°C transition)

    • Oxidative stress (H₂O₂, menadione)

    • Nutrient limitation (carbon, nitrogen, sulfur)

    • pH stress

    • Osmotic stress

  • Measure growth rates, morphological changes, and survival

• Transcriptomic and proteomic analyses:

  • Perform RNA-Seq comparing wild-type and MRI1-deficient strains under stress

  • Conduct proteomics to identify changes in protein expression and post-translational modifications

  • Focus on known stress response pathways and potential compensatory mechanisms

• Metabolic flexibility assessment:

  • Analyze changes in methionine metabolism under stress conditions

  • Track metabolic flux using labeled substrates

  • Measure energy status (ATP/ADP ratio) and redox balance (GSH/GSSG ratio)

• Host-relevant conditions:

  • Simulate macrophage phagolysosome conditions (low pH, oxidative stress, nutrient limitation)

  • Co-culture with host cells to assess survival and morphological transitions

  • Measure virulence factor expression in MRI1-deficient versus wild-type strains

These experimental approaches collectively provide insights into whether MRI1 contributes to stress adaptation directly through its enzymatic function or indirectly through signaling pathways and protein interactions.

How can recombinant P. marneffei MRI1 be utilized for developing diagnostic tools?

While specific information on MRI1 as a diagnostic target is not detailed in the provided literature, experiences with other P. marneffei proteins like Mp1p suggest potential approaches . Researchers interested in developing MRI1-based diagnostics should consider:

• Antibody-based detection methods:

  • Generate monoclonal and polyclonal antibodies against recombinant MRI1

  • Develop sandwich ELISA formats for antigen detection in clinical samples

  • Create lateral flow immunoassays for point-of-care testing

  • Compare sensitivity and specificity with existing diagnostic methods

• Nucleic acid-based detection:

  • Design PCR primers or LAMP (Loop-mediated isothermal amplification) assays targeting the MRI1 gene

  • Develop quantitative PCR methods for fungal burden assessment

  • Create multiplex assays detecting multiple P. marneffei targets simultaneously

• Evaluation with clinical samples:

  • Test assays with various sample types (blood, tissue, bronchoalveolar lavage)

  • Establish sensitivity, specificity, positive and negative predictive values

  • Compare performance in different patient populations (HIV-positive vs. HIV-negative)

The table below summarizes comparative data from a hypothetical evaluation of different diagnostic approaches targeting P. marneffei proteins:

These approaches should be evaluated against gold standard methods (culture, histopathology) to determine their potential utility in clinical settings.

What methodologies are appropriate for investigating potential cross-reactivity between P. marneffei MRI1 and homologous proteins in other fungi?

Cross-reactivity is an important consideration for both diagnostic development and understanding of host immune responses. Researchers should employ several complementary approaches:

• Computational analysis:

  • Perform sequence alignments to identify conserved epitopes

  • Use epitope prediction algorithms to locate potentially immunogenic regions

  • Construct phylogenetic trees to understand evolutionary relationships

• Antibody cross-reactivity testing:

  • Express recombinant MRI1 proteins from multiple fungal species

  • Conduct Western blots, ELISAs, and immunoprecipitation with antibodies raised against P. marneffei MRI1

  • Perform epitope mapping to identify the specific regions recognized

• T-cell response analysis:

  • Generate overlapping peptide libraries covering the MRI1 sequence

  • Test T-cell reactivity against peptides from P. marneffei and related fungi

  • Identify MHC binding motifs that might contribute to cross-recognition

• Clinical sample testing:

  • Evaluate serum samples from patients with various fungal infections

  • Assess cross-reactivity patterns in different geographic regions

  • Compare results between immunocompetent and immunocompromised patients

This methodological framework helps determine the specificity of MRI1 as a potential diagnostic target and provides insights into shared antigenic determinants that might influence immune recognition across fungal species.

How can comparative studies of MRI1 across different P. marneffei isolates inform epidemiological research?

Genetic and functional variation in MRI1 across P. marneffei isolates could provide valuable insights for epidemiological studies. Researchers should consider:

• Sequence variation analysis:

  • Sequence the MRI1 gene from clinical and environmental isolates

  • Identify polymorphisms and their distribution patterns

  • Correlate sequence variations with geographic origins of isolates

  • Construct phylogenetic networks to trace transmission patterns

• Functional characterization:

  • Compare enzymatic activities of MRI1 variants

  • Assess differences in non-catalytic functions related to invasion

  • Evaluate temperature-dependent expression and activity

  • Test stress responses across different isolates

• Clinical correlation studies:

  • Analyze potential associations between MRI1 variants and:

    • Disease severity

    • Treatment outcomes

    • Host factors (HIV status, genetic background)

    • Geographic clustering

• Evolutionary analysis:

  • Calculate selective pressure on different domains of MRI1

  • Identify regions under positive or purifying selection

  • Compare variation rates with other housekeeping genes and virulence factors

  • Develop molecular clock models to estimate divergence times

These approaches collectively contribute to understanding the population structure and evolution of P. marneffei, potentially revealing patterns of spread, adaptation to different hosts or environments, and emergence of variants with altered virulence or drug susceptibility profiles.